Janus registry results
This article was originally published in The Gray Sheet
Executive Summary
Six-month clinical results from Sorin Group's e-Janus international "real-world" registry - which has thus far enrolled over 2,500 patients at more than 80 centers worldwide - show a 4.3% major adverse cardiac events (MACE) rate and a 3.1% target lesion revascularization (TLR) rate for the 587 patients for which data has been collected. For the approximately 133 cases of high-risk acute myocardial infarction, a 3% MACE rate, 2.2% TLR rate and 0% late stent thrombosis rate were reported...
You may also be interested in...
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.